Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 10/20 | 0.56 |
| ▸ | NPC1 | O15118 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17761981 | 0.85 | MAPT (0.61) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL13732349 | 0.84 | ALDH1A1 (0.43) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL3066648 | 0.84 | ALDH1A1 (0.60) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL2791167 | 0.84 | ALDH1A1 (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL21938816 | 0.81 | RAB9A (0.66) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL1225966 | 0.81 | ALDH1A1 (0.59) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL23189127 | 0.80 | ALDH1A1 (0.52) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL2131964 | 0.79 | TP53 (0.50) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL17761982 | 0.78 | ALDH1A1 (0.50) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPK1 | |
| SCHEMBL744240 | 0.76 | NOTUM (0.48) | ALDH1A1SMN1; SMN2MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20200115350-A1 | Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION | 2020-04-16 | — | — | US | disclosed |
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| WO-2008130322-A1 | NOVEL 5-HETEROCYCLYL-CHROMANE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008043263-A1 | ISOXAZOLE DERIVATIVES AND METHODS OF TREATING DISEASES | DOU, DEXIAN (CN) | 2008-04-17 | — | — | WO | disclosed |
| US-20080085912-A1 | Isoxazole derivatives and methods of treating diseases | UNITECH PHARMACEUTICALS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085912-A1 | Isoxazole derivatives and methods of treating diseases | UNITECH PHARMACEUTICALS, INC. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085912-A1 | Isoxazole derivatives and methods of treating diseases | HLA-DRB1, XDH, EPX | ALDH1A1 749/4885RAB9A 4112/4885NPC1 1915/4885 |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | ALDH1A1 373/4885RAB9A 808/4885NPC1 2706/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | ALDH1A1 493/4885RAB9A 334/4885NPC1 1167/4885 |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | ALDH1A1 2895/4885RAB9A 1179/4885NPC1 1282/4885 |
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | ALDH1A1 973/4885RAB9A 785/4885NPC1 747/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | ALDH1A1 2324/4885RAB9A 2257/4885NPC1 2053/4885 |
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | CYP3A7, CYP2C19, CYP3A5 | ALDH1A1 560/4885RAB9A 2602/4885NPC1 1020/4885 |
| US-20200115350-A1 | Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors | HDAC1, HDAC7, HDAC5 | ALDH1A1 166/4885RAB9A 3174/4885NPC1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.